Calliditas Therapeutics is a Sweden-based biopharmaceutical company focused on developing and commercializing treatments for rare renal and autoimmune diseases. Headquartered in Stockholm, the company operates in Europe and the United States.
Its lead therapy is a targeted-release budesonide for primary IgA nephropathy, marketed as Tarpeyo in the U.S. and Kinpeygo in Europe/UK. Calliditas also advances a pipeline that includes setanaxib, an oral NADPH oxidase (NOX) inhibitor being evaluated for fibrotic and oncology indications. The company’s shares trade on Nasdaq Stockholm and its American Depositary Shares on the Nasdaq Global Select Market.
The acquisition will be executed through a voluntary tender offer, with major shareholders committed. It aligns with Asahi Kasei’s strategy to expand in healthcare, focusing on R&D and unmet medical needs.
